Podcasts about neoplastic

For the first time in more than a decade, a new Janus kinase (JAK) inhibitor has been approved for veterinary use in the United States. In this episode of Clinician's Brief Partner Podcast, Dr. Beth invites dermatologist Dr. Andrew Rosenberg to share everything practitioners need to know when it comes to using JAK inhibitors in practice, from the benefits of having options within the drug class to the implications of the boxed warning for the new option.Sponsored by Elanco INDICATIONSZenrelia is indicated for control of pruritus associated with allergic dermatitis and control of atopic dermatitis in dogs at least 12 months of age.IMPORTANT SAFETY INFORMATIONRead the entire package insert before using this drug, including the Boxed Warning. For Full prescribing information call 1 888 545 5973 or visit www.elancolabels.com/us/zenreliaWARNING: VACCINE-INDUCED DISEASE AND INADEQUATE IMMUNE RESPONSE TO VACCINES. Based on results of the vaccine response study, dogs receiving Zenrelia are at risk of fatal vaccine-induced disease and inadequate immune response to vaccines. Discontinue Zenrelia for at least 28 days to 3 months prior to vaccination and withhold Zenrelia for at least 28 days after vaccination. Dogs should be up to date on vaccinations prior to starting Zenrelia. Do not use in dogs less than 12 months old or dogs with a serious infection. Monitor dogs for infections because Zenrelia may increase susceptibility to opportunistic infections. Neoplastic conditions (benign and malignant) were observed during clinical studies. Consider the risks and benefits of treatment in dogs with a history of recurrence of these conditions. The most common adverse reactions were vomiting, diarrhea and lethargy. Zenrelia has not been evaluated in breeding, pregnant, or lactating dogs and concurrent use with glucocorticoids, cyclosporine, or other systemic immunosuppressive agents has not been tested. For full prescribing information see package insert.Zenrelia, Elanco, and the diagonal bar logo are trademarks of Elanco or its affiliates. PM-US-24-2291 Contact us:Podcast@briefmedia.comWhere to find us:Cliniciansbrief.com/podcastsFacebook.com/clinciansbriefTwitter: @cliniciansbriefInstagram: @clinicians.briefThe Team:Beth Molleson, DVM - HostSarah Pate - Producer & Project Manager, Brief StudioRandall Stupka - Podcast Production & Sound Editing

BUFFALO, NY- December 10, 2024 – A new #research paper was #published in Aging (listed by MEDLINE/PubMed as "Aging (Albany NY)" and "Aging-US" by Web of Science) Volume 16, Issue 21 on November 18, 2024, entitled, “Prostaglandin E2 regulates senescence and post-senescence neoplastic escape in primary human keratinocytes.” Researchers Elise Srour, Nathalie Martin, Claire Drullion, Clémentine De Schutter, Joëlle Giroud, Adrien Pioger, Julie Deslé, Laure Saas, Joe Nassour, Julien Théry, Gauthier Decanter, Nicolas Penel, Chantal Vercamer, Clara Salazar-Cardozo, Corinne Abbadie, and Olivier Pluquet from CNRS, University of Lille, the Oscar Lambret Center, and the University of Colorado School of Medicine have revealed how a molecule called Prostaglandin E2 (PGE2) influences skin aging and cancer risk. Their study shows that PGE2 not only drives skin cells to age but also enables some of these aging cells to bypass natural limits and develop into pre-cancerous cells. This process provides insights into why older skin is more susceptible to cancer. The study focused on keratinocytes, the primary cells in the outer layer of the skin. As these cells age, they enter a state called senescence, where they stop dividing to prevent damaged cells from turning cancerous. While this process typically serves as a protective mechanism, the researchers found that, in certain cases, some senescent cells can escape this state, re-enter the cell cycle, and acquire characteristics of early cancer. By examining keratinocytes from donors of different ethnicities and ages, the researchers identified the PTGS2/PGE2/EP4 pathway as a key driver of this escape process. The researchers show that blocking PGE2 or its associated pathway reduced the chances of aged cells becoming precancerous. This suggests that drugs targeting this pathway, including some anti-inflammatory medications already in use, might be repurposed to slow skin aging and prevent early-stage skin cancers. Additionally, the study also found that PGE2 levels increase in the skin as it ages, further supporting its role in skin health and disease. "These results indicate that the PTGS2/PGE2/EP4 pathway is required to induce and maintain the senescent phenotype of NHEKs, and that PGE2 level is a potential determinant of the initial steps of the age-related oncogenic process." The team also highlighted the broader implications of their work. The PTGS2/PGE2/EP4 pathway is not only linked to skin health but also to age-related inflammation, a condition that contributes to several diseases. By addressing this pathway, researchers hope to address not only skin aging but other health challenges linked to aging and chronic inflammation. In conclusion, this study reveals important molecular drivers of skin aging and early cancer, leading the way for new approaches that can promote healthier skin. DOI - https://doi.org/10.18632/aging.206149 Corresponding author - Olivier Pluquet - olivier.pluquet@ibl.cnrs.fr Video short - https://www.youtube.com/watch?v=4aNf3X2RJSw About Aging-US The mission of the journal is to understand the mechanisms surrounding aging and age-related diseases, including cancer as the main cause of death in the modern aged population. The journal aims to promote 1) treatment of age-related diseases by slowing down aging, 2) validation of anti-aging drugs by treating age-related diseases, and 3) prevention of cancer by inhibiting aging. (Cancer and COVID-19 are age-related diseases.) Please visit our website at https://www.Aging-US.com​​ and connect with us: Facebook - https://www.facebook.com/AgingUS/ X - https://twitter.com/AgingJrnl Instagram - https://www.instagram.com/agingjrnl/ YouTube - https://www.youtube.com/@AgingJournal LinkedIn - https://www.linkedin.com/company/aging/ Pinterest - https://www.pinterest.com/AgingUS/ Spotify - https://open.spotify.com/show/1X4HQQgegjReaf6Mozn6Mc MEDIA@IMPACTJOURNALS.COM

Sponsored by Elanco. Unlike conventional treatments for canine allergic and atopic dermatitis, novel targeted therapies provide rapid relief with a reduced risk for adverse events. In this podcast, Andrew Rosenberg, DVM, and Adam Christman, DVM, MBA, react to the availability of a once-daily oral JAK inhibitor, highlighting it as a significant advancement in managing difficult skin conditions in dogs. Learning Objectives: Understand the various causes of canine allergic and atopic dermatitis. Gain insight into using available treatment options to manage canine allergic and atopic dermatitis. Learn how Zenrelia™ (ilunocitinib tablets) can be used to offer dogs relief from pruritus associated with allergic and atopic dermatitis.  DISCLAIMER Zenrelia, Elanco, and the diagonal bar logo are trademarks of Elanco or its affiliates. PM-US-24-1649 INDICATIONS Zenrelia is indicated for control of pruritus associated with allergic dermatitis and control of atopic dermatitis in dogs at least 12 months of age. IMPORTANT SAFETY INFORMATION Read the entire package insert before using this drug, including the Boxed Warning. For Full prescribing information call 1 888 545 5973 or visit www.elancolabels.com/us/zenrelia WARNING: VACCINE-INDUCED DISEASE AND INADEQUATE IMMUNE RESPONSE TO VACCINES. Based on results of the vaccine response study, dogs receiving Zenrelia are at risk of fatal vaccine-induced disease and inadequate immune response to vaccines. Discontinue Zenrelia for at least 28 days to 3 months prior to vaccination and withhold Zenrelia for at least 28 days after vaccination. Dogs should be up to date on vaccinations prior to starting Zenrelia. Do not use in dogs less than 12 months old or dogs with a serious infection. Monitor dogs for infections because Zenrelia may increase susceptibility to opportunistic infections. Neoplastic conditions (benign and malignant) were observed during clinical studies. Consider the risks and benefits of treatment in dogs with a history of recurrence of these conditions. The most common adverse reactions were vomiting, diarrhea and lethargy. Zenrelia has not been evaluated in breeding, pregnant, or lactating dogs and concurrent use with glucocorticoids, cyclosporine, or other systemic immunosuppressive agents has not been tested. For full prescribing information see package insert.

In today's VETgirl online veterinary CE podcast, we review the clinical signs, clinical course and prognosis for dogs diagnosed with pericardial effusion secondary to either left atrial rupture from myxomatous mitral valve disease versus those with neoplastic cardiac tamponade. This is based off a recent study by Sugiura et al entitled “Retrospective evaluation of clinical signs, clinical course, and prognosis between dogs with left atrial rupture secondary to myxomatous mitral valve disease and those with neoplastic cardiac tamponade (2015-2019): 70 cases.”

◆Voicy新チャンネル開設！【獣医Sara先生のペットの暮らしと健康】 https://bit.ly/3sLljup ＜今週のライブ情報

The Chloride Intracellular Channel 1 (CLIC1) protein appears to hold the key to understanding the anti-proliferative action of metformin, according to laboratory evidence discussed at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics held in October 2023, in Boston. At the conference, Michele M. Mazzanti, PhD, from the Department of Bioscience, at Milan University, Italy, reported his group’s recent findings about the possibility of using metformin to reduce glioblastoma mortality. Afterwards he discussed the study and its clinical implications with OncTimes Talk correspondent, Peter Goodwin.

A new research perspective was published in Oncotarget's Volume 14 on April 14, 2023, entitled, “Adopted neoplastic cells and the consequences of their existence.” In this research perspective, researcher Yuri Lazebnik from Lerna Consulting begins by explaining a view that guides the bulk of cancer research and oncology: each neoplastic cell in a tumor is a genetic offspring of another neoplastic cell. “Yet, analyzing tumors from transplant patients has revealed that some normal migratory cells adopt the phenotype of neoplastic cells without acquiring their genome, thus becoming what I suggest to call adopted neoplastic cells.” This commentary reviews the evidence for the existence of adopted neoplastic cells, outlines the consequences of their presence, and discusses what kind of cells can be adopted, how and why. “Finally, as experiments with humans can go only that far, and fortunately so, testing the hypotheses we have discussed will require experimental systems, such as human tumor explants which have been explored to reveal intercellular bridging [129, 130] and chimeric animals designed to monitor cell fate, cell fusion, and component transfer [206].” DOI - https://doi.org/10.18632/oncotarget.28408 Correspondence to - Yuri Lazebnik - yuri@lernaconsulting.com Video short - https://www.youtube.com/watch?v=THtJfHLi_FM Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28408 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, tumor microenvironment, horizontal oncogenesis, intercellular bridges, cell fusion, cell repair About Oncotarget Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science. To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: SoundCloud - https://soundcloud.com/oncotarget Facebook - https://www.facebook.com/Oncotarget/ Twitter - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Media Contact MEDIA@IMPACTJOURNALS.COM 18009220957

Link to bioRxiv paper: http://biorxiv.org/cgi/content/short/2023.06.28.544680v1?rss=1 Authors: Vandepas, L. E., Crim, R. N., Gilbertson, E., Yonemitsu, M. A., Unsell, E., Metzger, M. J., Lacy-Hulbert, A., Goetz, F. W. Abstract: Disseminated neoplasia (DN) is a form of cancer in bivalve molluscs that has been reported in some cases to be a transmissible cancer. Neoplastic cells are highly proliferative, and infection is often lethal. Some commercially valuable bivalve species (mussels, cockles, soft-shell clams, oysters) are affected by outbreaks of disseminated neoplasia, making disease diagnosis and mitigation an important issue in aquaculture and ecological restoration efforts. Here we describe a minimally invasive, non-lethal method for high-throughput screening for disseminated neoplasia in basket cockles (Clinocardium nuttallii). Basket cockles are native to the North American Pacific coast from California to Alaska. There is recent concern from some Coast Salish Tribes regarding an observed long-term decline in cockle populations in Puget Sound, WA. This has led to increased interest in monitoring efforts and research to improve our understanding of the mechanisms of observed basket cockle population dynamics, including assessing prevalence of disease, such as disseminated neoplasia. The rapid, non-lethal hemolymph smear screening method presented here to diagnose DN in adult C. nuttallii can be applied at field sites at low financial cost, and in a validation study of 29 animals the results were identical to that of the gold standard method, tissue histology. Due to the similar morphology of DN in different bivalves, this method can likely be generally applied for use in any bivalve species. Copy rights belong to original authors. Visit the link for more info Podcast created by Paper Player, LLC

Throughout your clinical career, physical assessments will be integral in crystallising a naturopathic diagnosis and directing care. Many assessments seem mundane (the expert clinician will often appraise their patients subconsciously), but done correctly and with cognisance they can reveal hidden pathology that is often missed by those who skip them . Take Blood Pressure (BP), for instance. It is one of the cardinal vital signs along with pulse, respirations and temperature, but how often do we repeat these measurement in our patients? But let's not stop at the usual medical assessments. What about patients' posture, symmetry, vitality, fingernails, eyes, hair, gait, thyroid palpation...and how much can we attend to all these assessments when consulting remotely? Today Katie Barron takes us through how critical these and other physical assessments can be in choosing the correct course of action and cementing your place as a responsible healthcare professional, not the least of which is referral to appropriate medical care when necessary. Katie is masterful at being present with her patients and she demands excellence in those she tutors.   REFERENCESKatie Barron- Free Stuff for PracsKatie Barron- Mini-TrainingsKatie Barron's Full course (Contact Katie for Discount) Aetiological Sieve Mnemonic: See("C") That Italian Vase Now Has Many New Dried Peas In It(Stands for the initials: C, T, I, V, N, H, M, N, D, P, I, I.)Possible causes: Congenital, Trauna, Inflammation (Infection or Autoimmune), Vascular, Neoplastic, Hormonal, Musculoskeletal, Nutritional, Drugs, Psychiatric, Idiopathic, Idiosyncratic. Rehman R, et al. Blood Pressure Measurement. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-.  [Updated 2022 Dec 28] (Accessed 2023 Feb 22).  Sapra A, et al. Vital Sign Assessment. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. [Updated 2023 May 1] (Accessed 2023 Feb 22). Belleza M. Head-to-Toe Assessment: Complete Physical Assessment Guide. Fundamentals of Nursing. NurseLabs. [Updated 2023 Jul 2] (Accessed 2023 Mar 01).  The Stanford Medicine 25. Stanford Medicine. Stanford University. (Accessed 2023 Mar 01). NB: ALWAYS REMAIN WITHIN SCOPE OF PRACTICE! Natural Medicine Podcast and Natural Medicine Partners Pty Ltd shall be held harmless in all undertakings and accept no responsibility for your actions. Refer to Natural Medicine Partners Full Terms and Conditions.

Sure, dermatologists manage a lot of allergies. However, there are signs that should raise a red flag that you AREN'T dealing with an allergic patient? Distribution of lesions seem off? The history doesn't jive with allergies? Not responding to traditional therapies? Tune into this week's episode of the podcast to learn more!

PAPER 1Authors: Vijenthira A. et al. (Princess Margaret, Toronto)Title: Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patientsDescription:⦁ About a third of hospitalized adult patients with hematologic malignancy and COVID-19 – dye. ⦁ No need to withhold anti-cancer treatment from these patients.Paper 2Authors: P. Fenaux; U. Platzbecker; A. List and colleagues, multicenterTitle: Luspatercept in Patients with Lower-Risk Myelodysplastic SyndromesDescription: Luspatercept, an activin receptor derived agent, improves the anemia in LR-MDS patients. Thus, we have another approved anti-anemic agent in addition to ESAs for these patients.Paper 3Authors: David Henry et al. , multicenter ((Disclosure – I am a co-author)Title: Oral Roxadustat Demonstrates Efficacy in Anemia Secondary to Lower-Risk Myelodysplastic Syndrome Irrespective of Ring Sideroblasts and Baseline Erythropoietin LevelsDescription: Roxadustat, an oral hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor, is another investigated effective agent for the anemia in LR-MDS.Paper 4Title:  Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AMLAuthors: M.A. Sekeres, and colleagues, multicenter, multunationalDescription:  Pevonedistat, a NEDD8 inhibitor, together with azacitidine, improves the response and prognosis in HR-MDS patients.

This episode covers pancreatic cystic neoplasms including:Neoplastic mucinous cystic lesions- Intraductal papillary mucinous neoplasms (IPMNs)- Mucinous cystic neoplasms (MCNs)Neoplastic non-mucinous cystic lesions- Serous cystic neoplasms / serous cystadenomas- Solid pseudopapillary neoplasmsWe cover their workup, radiological appearance, demographic information, FNA results, likely cytology and management of these lesionsWe also briefly mention non-neoplastic cystic lesions including simple cysts and pseudocysts, as well as the potential that ductal adenocarcinomas and neuroendocrine tumours have to have cystic degeneration.DisclaimerThe information in this podcast is intended as a revision aid for the purposes of the General Surgery Fellowship Exam.This information is not to be considered to include any recommendations or medical advice by the author or publisher or any other person. The listener should conduct and rely upon their own independent analysis of the information in this document.The author provides no guarantees or assurances in relation to any connection between the content of this podcast and the general surgical fellowship exam.  No responsibility or liability is accepted by the author in relation to the performance of any person in the exam.  This podcast is not a substitute for candidates undertaking their own preparations for the exam.To the maximum extent permitted by law, no responsibility or liability is accepted by the author or publisher or any other person as to the adequacy, accuracy, correctness, completeness or reasonableness of this information, including any statements or information provided by third parties and reproduced or referred to in this document. To the maximum extent permitted by law, no responsibility for any errors in or omissions from this document, whether arising out of negligence or otherwise, is accepted.The information contained in this podcast has not been independently verified.© Amanda Nikolic 2021

PAPER 1Authors: Vijenthira A. et al. (Princess Margaret, Toronto)Title: Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patientsDescription:⦁ About a third of hospitalized adult patients with hematologic malignancy and COVID-19 – dye. ⦁ No need to withhold anti-cancer treatment from these patients. Paper 2Authors: P. Fenaux; U. Platzbecker; A. List and colleagues, multicenterTitle: Luspatercept in Patients with Lower-Risk Myelodysplastic SyndromesDescription: Luspatercept, an activin receptor derived agent, improves the anemia in LR-MDS patients. Thus, we have another approved anti-anemic agent in addition to ESAs for these patients. Paper 3Authors: David Henry et al. , multicenter ((Disclosure – I am a co-author)Title: Oral Roxadustat Demonstrates Efficacy in Anemia Secondary to Lower-Risk Myelodysplastic Syndrome Irrespective of Ring Sideroblasts and Baseline Erythropoietin LevelsDescription: Roxadustat, an oral hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor, is another investigated effective agent for the anemia in LR-MDS. Paper 4Title: Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AMLAuthors: M.A. Sekeres, and colleagues, multicenter, multunationalDescription: Pevonedistat, a NEDD8 inhibitor, together with azacitidine, improves the response and prognosis in HR-MDS patients.

This episode covers neoplastic progression!

> Lung Cancer #1 cause of cancer related deaths 85% of cases are associated with smoking Multiple exposure and exposure to other toxins increases risk Five year survival rate is 15% Small Cell and Non Small Cell Complications SVC syndrome […] The post S2 E059 Pulm Neoplastic Disease appeared first on Physician Assistant Exam Review.

The differential diagnosis is long... You need an approach.   The Rule of 3s: 3 minutes -- Traumatic 3 days -- Inflammatory 3 months -- Neoplastic 3 years -- Congenital   3 Minutes?  Traumatic   3 Days?  Inflammatory [caption id="attachment_1777" align="alignnone" width="262"] Cervical Node Chain; Lymphadenopathy[/caption] [caption id="attachment_1773" align="alignnone" width="298"] Bacterial Lymphadenitis[/caption] [caption id="attachment_1772" align="alignnone" width="300"] Bacterial lymphadenitis with small abscess[/caption] [caption id="attachment_1771" align="alignnone" width="300"] Large Abscess[/caption]   3 Months?  Neoplastic   3 Years?  Congenital [caption id="attachment_1784" align="alignnone" width="300"] Thyroglossal Duct Cyst[/caption] [caption id="attachment_1783" align="alignnone" width="300"] Thyroglossal Duct Cyst[/caption] [caption id="attachment_1776" align="alignnone" width="278"] Branchial Cleft Cyst[/caption] [caption id="attachment_1775" align="alignnone" width="263"] Branchial Cleft Cyst[/caption] [caption id="attachment_1774" align="alignnone" width="233"] Branchial Cleft Cyst[/caption] [caption id="attachment_1779" align="alignnone" width="300"] Cystic Hygroma[/caption]   [caption id="attachment_1778" align="alignnone" width="235"]  Cystic Hygroma[/caption]   Selected References Enepekides DJ. Management of congenital anomalies of the neck. Facial Plast Surg Clin North Am 2001; 9:131. Lin ST, Tseng FY, Hsu CJ, et al. Thyroglossal duct cyst: a comparison between children and adults. Am J Otolaryngol 2008; 29:83. Mandell DL. Head and neck anomalies related to the branchial apparatus. Otolaryngol Clin North Am 2000; 33:1309. Marler JJ, Mulliken JB. Current management of hemangiomas and vascular malformations. Clin Plast Surg 2005; 32:99. Silverman, J. F., Gurley, A. M., Holbrook, C. T., Joshi, V. V. (1991) Pediatric fine needle aspiration biopsy. American Journal of Clinical Pathology 95: 653–659 Sonnino RE, Spigland N, Laberge JM, Desjardins J, Guttman FM. Unusual patterns of congenital neck masses in children. J Pediatr Surg. 1989 Oct;24(10):966-9.

In this podcast, Dr. Wade Swenson, an otolaryngologist with Ridgeview Specialty Clinics, provides an overview of the work-up and management of common pediatric neck masses. Objectives:    Upon completion of this podcast, participants should be able to: Identify the most appropriate algorithm to work-up and manage pediatric neck masses. Choose a focused differential diagnosis of a pediatric neck mass. Recognize when a referral to an otolaryngologist for a pediatric neck mass is recommended. CME credit is only offered to Ridgeview Providers for this podcast activity. Complete and submit the online evaluation form, after viewing the activity.  Upon successful completion of the evaluation, you will be e-mailed a certificate of completion within 2 weeks.  You may contact the accredited provider with questions regarding this program at  rmccredentialing@ridgeviewmedical.org. Click on the following link for your CME credit: CME Evaluation: "Pediatric Neck Masses" (**If you are listening to the podcasts through iTunes on your laptop or desktop, it is not possible to link directly with the CME Evaluation for unclear reasons. We are trying to remedy this. You can, however, link to the survey through the Podcasts app on your Apple and other smart devices, as well as through Spotify, Stitcher and other podcast directory apps and on your computer browser at these websites. We apologize for the inconvenience.)  The information provided through this and all Ridgeview podcasts as well as any and all accompanying files, images, videos and documents is/are for CME/CE and other institutional learning and communication purposes only and is/are not meant to substitute for the independent medical judgment of a physician, healthcare provider or other healthcare personnel relative to diagnostic and treatment options of a specific patient's medical condition.”   FACULTY DISCLOSURE ANNOUNCEMENT  It is our intent that any potential conflict should be identified openly so that the listeners may form their own judgments about the presentation with the full disclosure of the facts. It is not assumed any potential conflicts will have an adverse impact on these presentations. It remains for the audience to determine whether the speaker’s outside interest may reflect a possible bias, either the exposition or the conclusions presented. Planning committee members and presenter(s) have disclosed they have no significant financial relationship with a pharmaceutical company and have disclosed that no conflict of interest exists with the presentation/educational event. SHOW NOTES: CHAPTER 1: Pediatric neck masses fall into 3-categories:  Inflammatory, Congenital, and Neoplastic.  Seventy-five percent (75%) of neck masses are inflammatory, 20% congenital, and 5% or fewer are consistent with malignancy. The American Academy of Family Practice has a great algorithm on Pediatric Head and Neck masses. The majority of children with enlarged lymph nodes are largely reactive in nature. Most neck masses that are rubbery, mobile and B/L, are indicative of inflammatory in nature. Five (5) or more CTs of head and neck region can increase pediatric malignancy 3-fold. Palpate the parotids, submental, anterior SCM, posterior triangle, supraclavicular lymph nodes. Specific characteristics of a neck mass its midline or lateral.  The size, fixed or mobile, painful or non-tender, firm or soft, solitary or multiple nodes, skin changes. Do an oral and dental exam. Staph and strep are the bacterial causes of most inflammatory neck masses. Antibiotics typically used include: Keflex, Augmentin, and Clindamycin for 10-days; recheck in 3-days to document improvement or continued concern. Atypical mycobacterium infection is generally the cause of chronic inflammatory granulomatous processes.  Often found in the submandibular and periparietal lymph nodes. Generally unilateral and non-tender lymph nodes. Workup includes: PPD skin tests, Bartonella Henslae (or Cat Scratch Fever) and Toxoplasmosis. CHAPTER 2: Physical location and history will guide you to the diagnosis of thyroglossal and brachiocleft cyst. Up to 50% of cysts present infected. Thyroglossal cyst present in the midline from hyoid bone to thyroid isthmus. They tend to be smooth and will often be raised when a child sticks out their tongue. The average of diagnosis is around 6-yrs. of age. About 40% present before the age of 10. Typical treat similar to infected lymph node. With a course of abx and observation to "cool down" the neck mass for 5-6 weeks and then usually surgery. I&D are not recommended as it can cause a fistula track. Imaging choice for a thyroglossal cyst is ultrasound. Furthermore, confirming normal thyroid function in imperative, as you do not want to be fooled by an ectopic thyroid. It is acceptable for the primary care to initiate abx therapy with referral to ENT 1-2 weeks after abx management for recheck and further evaluation. ENT typically recommends surgery for congenital neck masses b/c they do not resolve on their own. Brachiocleft cyst represents 1/3 of congenital neck masses. Most common is a 2nd brachiocleft cyst. Present high in the neck anterior and deep to the SCM border below the angle of the mandible. Ultrasound you guessed it is the imaging modality of choice. One limitation of US is not great at differentiating a lymph node vs. cancer. That's where history and physical exam findings come into play. As an example - Is it a supraclavicular mass, firm, fixed, hard with dimensions greater than 3cm, which is going to be more concern for cancer. Most common cause of pediatric head and neck CA is Hodgkin's lymphoma. Look for fever, chills, malaise, night sweat, weight loss, pallor, fatigue, and failure to thrive. Vascular anomalies are relatively uncommon and are typically referred to as lymphatic malformation. Typically referred to pediatric ENT at Children's or the U. Another name for these lymphatic malformation are also called Cystic Hygromas. Hygromas are typically soft, doughy, trans-illuminate - found commonly in posterior triangle. US are initial imaging choice, however CT or MR can help with delineating the extent of the hygroma. There is about a 5% or fewer risk of malignancy in children with persistent head or neck masses. FNA's are NOT recommended in children. Forty to 50% of cancers in children with head and neck masses are lymphomas. Incisional or excisional biopsy for larger neck masses is generally the next step in evaluation and treatment. SUMMARY OF EVALUATING PEDIATRIC NECK MASSES: Evaluation of pediatric neck masses include: observation, antibiotics, imaging with US to differentiate if lymph node remains - consider obtaining PPD, bartonella and toxoplasmosis titer - looking for granulomatous disease. Next step is surgical removal of the lymph node. As far as labs go - often times the ENT will have the specific titers they want for ruling out certain disease processes. Leave the detailed lab ordering to ENT. When the lymph node is finally excised, generally sent for pathology and culture. RECAP: Neck masses are common. Majority are benign in etiology. They fall into 3-categories: inflammatory, congenital, or neoplastic. Characterize the neck mass with a detailed physical exam. Location, size, mobility, consistency, single or multiple, unilateral or bilateral. Is there fever or chills, accompanied with sxs? Managed with observation and a course of abx. No improvement, consider an US to further differentiate the mass. No improvement 4-6 weeks, send off to ENT for further evaluation.

Jason interviews Dr. Carlo Maley on the ways that Nature has already beaten cancer.   Dr. Maley received his Ph.D. from MIT in computer science (computational biology) in 1998 working with Rodney Brooks and Michael Donoghue (at Harvard at the time), his M.Sc. Zoology (evolutionary theory) from University of Oxford in 1993 working with W.D. Hamilton, and his B.A. in computer science and psychology from Oberlin College in 1991.   He went on to hold faculty positions at the Wistar Institute (2005-2010) and the University of California San Francisco (2010-2015) before joining Arizona State University in 2015.Maley is a Renowned Cancer Biologist, Evolutionary Biologist, and Computational Biologist.  Maley will discuss the findings from his TedxTalks Event: "How Nature Has Already Beat Cancer." (TEDxASU), published on 5/22/16.    Jason looks forward to interviewing Dr. Maley about his research which describes Twelve Examples of Animals Who Have Beat Cancer Through Evolution including such animals such as the elehpant, rhinocerous, giraffe, water buffalo, indian bison, polar bears and others.  Maley's team applies evolutionary and ecological theory to three problems in cancer: (1) Neoplastic progression: the evolutionary dynamics among cells of a tumor that drive progression from normal tissue to malignant cancers, (2) Acquired therapeutic resistance: the evolutionary dynamics by which our therapies select for resistance and we fail to cure cancer, and (3) the evolution of cancer suppression mechanisms in large, long-lived animals like elephants and whales (a problem called Peto's Paradox). They use genomic data mining, phylogenetics, computational modeling, as well as wet lab techniques to solve these problems. In all of this work, their goals are to develop better methods to prevent cancer and improve cancer management.  

Jason interviews Dr. Carlo Maley on the ways that Nature has already beaten cancer.   Dr. Maley received his Ph.D. from MIT in computer science (computational biology) in 1998 working with Rodney Brooks and Michael Donoghue (at Harvard at the time), his M.Sc. Zoology (evolutionary theory) from University of Oxford in 1993 working with W.D. Hamilton, and his B.A. in computer science and psychology from Oberlin College in 1991.   He went on to hold faculty positions at the Wistar Institute (2005-2010) and the University of California San Francisco (2010-2015) before joining Arizona State University in 2015. Maley is a Renowned Cancer Biologist, Evolutionary Biologist, and Computational Biologist.  Maley will discuss the findings from his TedxTalks Event: "How Nature Has Already Beat Cancer." (TEDxASU), published on 5/22/16.    Jason looks forward to interviewing Dr. Maley about his research which describes Twelve Examples of Animals Who Have Beat Cancer Through Evolution including such animals such as the elehpant, rhinocerous, giraffe, water buffalo, indian bison, polar bears and others.   Maley's team applies evolutionary and ecological theory to three problems in cancer: (1) Neoplastic progression: the evolutionary dynamics among cells of a tumor that drive progression from normal tissue to malignant cancers, (2) Acquired therapeutic resistance: the evolutionary dynamics by which our therapies select for resistance and we fail to cure cancer, and (3) the evolution of cancer suppression mechanisms in large, long-lived animals like elephants and whales (a problem called Peto’s Paradox). They use genomic data mining, phylogenetics, computational modeling, as well as wet lab techniques to solve these problems. In all of this work, their goals are to develop better methods to prevent cancer and improve cancer management.  

This week on PA Study Sesh we will be discussing disorders of the foot and ankle, bone tumors, and compartment syndrome. Ankle Dislocation Most commonly posteriorly (calcaneus goes posterior) Risk to peroneal n Sx: foot drop Tx: closed reduction & posterior splint Ankle Sprain MOI: inversion Anterior talofibular ligament (ATFL) #1 Eversion injury = deltoid … Continue reading Foot & Ankle; Compartment Syndrome; Neoplastic Disease →

Professor Irving L Weissman talks to ecancertv at AACR 2016 about his labs research into immune evasion of cancer cells. Calreticulin, which is normally down-regulated by stem cells transiting between bone marrow sites, is also blocked from the surface of cancer stem cells to prevent immune recognition. Normally, calreticulin acts as an “eat me signal” to macrophages, and by producing a humanised antibody towards it in treating leukaemia and solid tumours, Prof Weissman hopes to combine it with immunotherapeutics and recruit an immune response.

Dr. Ross Camidge talks about a clinical trial that will test to see if the drug tesevatinib will work to kill cancer that has progressed in the brains of EGFR-mutant lung cancer patients. The trial is scheduled to begin in late 2015 or early 2016.

Dr. Ross Camidge talks about a clinical trial that will test to see if the drug tesevatinib will work to kill cancer that has progressed in the brains of EGFR-mutant lung cancer patients. The trial is scheduled to begin in late 2015 or early 2016.

Dr. Ross Camidge talks about a clinical trial that will test to see if the drug tesevatinib will work to kill cancer that has progressed in the brains of EGFR-mutant lung cancer patients. The trial is scheduled to begin in late 2015 or early 2016.

01/13/2014 | MDCT of the Small Bowel: Neoplastic Disease Pt. 2

01/06/2014 | MDCT of the Small Bowel: Neoplastic Disease Pt. 1

Click here for audio of lecture.

October 18, 2011 Preventing Neoplastic Progression in IBD Thomas Ullman, MD Associate Professor of Medicine Mount Sinai School of Medicine, New York, NY

Enhanced Video PodcastAired date: 6/18/2008 3:00:00 PM Eastern Time

Enhanced Audio PodcastAired date: 6/18/2008 3:00:00 PM Eastern Time

06/20/2008 | CTA of the SMA and Celiac Axis Non-Neoplastic Disease

Fri, 1 Jan 1993 12:00:00 +0100 https://epub.ub.uni-muenchen.de/7512/1/7512.pdf Gratzl, Manfred; Lahr, G. ddc:610, Medi

Mon, 1 Jan 1990 12:00:00 +0100 https://epub.ub.uni-muenchen.de/9400/1/9400.pdf Manuelidis, L.; Borden, J.; Cremer, Thomas; Lichter, Peter; Ward, D. C. d

Mon, 1 Jan 1990 12:00:00 +0100 https://epub.ub.uni-muenchen.de/9401/1/9401.pdf Cremer, Thomas; Jauch, Anna; Emmerich, Patricia; Walt, H. dd

C3H 10T1/2 mouse-embryo fibroblasts were used for transformation experiments to study the effectiveness of various heavy ions with energies up to 20 MeV/u and LET values from 170 to 16.000 keV/μm. The transformation frequency per unit absorbed dose decreased with increasing ionization density; at the highest values of LET we found a decrease even of the transformation efficiency per unit fluence. Uranium ions at energies of 5, 9, and 16.3 MeV/u did not induced any transformation. In additional studies piimary Syrian hamster embryo cells (SHE) were exposed to heavy ions in order to characterize cytological and molecular changes which may be correlated with neoplastic transformation. Growth behaviour, chromosomal status, tumorigenicity in nude mice, and expression of oncogenes of transformed cell lines were examined.

Fri, 1 Jan 1988 12:00:00 +0100 https://epub.ub.uni-muenchen.de/9033/1/9033.pdf Kellerer, Albrecht M.; Fromke, E.; Fenn, S.; Trutschler, K.; Ponsel, G.; Hieber, L.